Technology ID
TAB-2895

A Novel Virus-Based Expression System

E-Numbers
E-181-2014-0
Lead Inventor
Moss, Bernard (NIAID)
Co-Inventors
Wyatt, Linda (NIAID)
Applications
Vaccines­­­
Therapeutics
Research Materials
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
  • Early-stage
  • In vitro data available
  • Prototype
Lead IC
NIAID
ICs
NIAID
The present invention is related to a recombinant viral vector for vaccines.

Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response.

The present novel virus-based expression vectors are non-replicating in human and animals, have high expression of exogenous genes to achieve strong immunogenicity, demonstrate low expression of vector proteins to minimize anti-vector immune responses and minimize competition with expression of recombinant proteins and are capable of stable propagation in a continuous cell line. The present virus based expression vectors may be suitable for manufacturing vaccines for inducing an immune response in vaccinated individuals.
Commercial Applications
  • Vaccine
  • Tool for studying immune responses
Competitive Advantages
  • Non-replicating in human and animals
  • Achieve high expression of recombinant genes
  • Low expression of vector genes
  • Stable propagation in a continuous cell line

Request More Info

Licensing Contact:
Hurley, Benjamin
benjamin.hurley@nih.gov

Related Inventions

Patents

  • Patent Cooperation Treaty
    (PCT) PCT/US2015/052295
    Filed on 2015-09-25
  • US
    Provisional (PRV) 62/055,989
    Filed on 2014-09-26
  • US Patent 10,894,966
    Filed on 2017-03-24

Collaborations

  • Collaboration

Collaboration Description

  • The National Institute of Allergy and Infectious Diseases, Laboratory of Viral Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize A Novel Virus-Based Expression System. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.gov.
Date Published